Regulatory
Corporate Information
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency
September 28, 2026
Press releases
Press Releases
This section contains official press releases issued by Egetis. These announcements include regulatory updates, corporate developments and information disclosed in accordance with applicable market regulations.
Search below for our latest press releases and company reports
Corporate Information
Emcitate® (tiratricol) Presentations at ETA and ESPE Congresses in September 2026
September 4, 2026
Corporate Information
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
September 3, 2026
Corporate Information
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
September 3, 2026
Corporate Information
Tiratricol Granted Orphan Drug Designation for MCT8 Deficiency in Japan
August 31, 2026
Regulatory
Report
Egetis’ Interim report Q2 2026
August 21, 2026
Corporate Information
Invitation to Presentation of Egetis’ Q2 2026 Report on August 21, 2026
August 7, 2026
Corporate Information
Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency
June 10, 2026
Regulatory
Corporate Action
Change in the number of shares and votes in Egetis Therapeutics
May 29, 2026
Corporate Information
Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026
May 19, 2026
Corporate Information
Exercise of options under employee stock option program and notification of insider trading
May 13, 2026
Corporate Information
Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026
May 7, 2026
Latest From LinkedIn
Explore